Now in its 12th year of operation, Dana-Farber/Harvard Cancer Center (DF/HCC) is the first consortium model, NCI-designated Comprehensive Cancer Center in the country. The consortium is comprised of 1,015 members from five principal Harvard-affiliated hospitals and two Harvard health science schools: Beth Israel Deaconess Medical Center (BIDMC), Brigham and Women's Hospital (BWH), Children's Hospital Boston (CHB), Dana-Farber Cancer Institute (DFCI), Harvard Medical School (HMS), Harvard School of Public Health (HSPH), and Massachusetts General Hospital (MGH). The progress presented in this proposal has required DF/HCC leadership, its combined resources, and, most importantly, its consortium structure. The overarching scientific vision is to unite the members. The research of the Center is carried out in Research Programs that cross both scientific and institutional boundaries. In addition, the Center supports Shared Resources dedicated to enhancing scientific efficiency available to all Center members. The unified clinical research infrastructure has made it easier for members to conduct clinical trials across the Center. Indirect indications of scientific progress are the substantial growth in the Center's gran portfolio, from $233 million in 1999 to $406 million in 2004, to $623 million in 2009, and the award of multiple translational grants that transcend organizational boundaries (e.g., SPOREs, SCORs, P01s, U01s, and SU2Cs). There is also an array of hypothesis-driven, Early Phase (pilot, I, I-II), and proof-of-concept trials, made possible through the development and execution of the Center, that are conducted daily across the consortium.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
3P30CA006516-47S3
Application #
8533071
Study Section
Subcommittee G - Education (NCI)
Program Officer
Ptak, Krzysztof
Project Start
1997-03-10
Project End
2016-11-30
Budget Start
2012-05-15
Budget End
2012-11-30
Support Year
47
Fiscal Year
2012
Total Cost
$50,000
Indirect Cost
$21,428
Name
Dana-Farber Cancer Institute
Department
Type
DUNS #
076580745
City
Boston
State
MA
Country
United States
Zip Code
02215
Santana-Codina, Naiara; Roeth, Anjali A; Zhang, Yi et al. (2018) Oncogenic KRAS supports pancreatic cancer through regulation of nucleotide synthesis. Nat Commun 9:4945
Cox, Andrew G; Tsomides, Allison; Yimlamai, Dean et al. (2018) Yap regulates glucose utilization and sustains nucleotide synthesis to enable organ growth. EMBO J 37:
Oxnard, Geoffrey R; Hu, Yuebi; Mileham, Kathryn F et al. (2018) Assessment of Resistance Mechanisms and Clinical Implications in Patients With EGFR T790M-Positive Lung Cancer and Acquired Resistance to Osimertinib. JAMA Oncol 4:1527-1534
Patil, Prasad; Parmigiani, Giovanni (2018) Training replicable predictors in multiple studies. Proc Natl Acad Sci U S A 115:2578-2583
Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404
Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917
Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121
Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538
Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228
Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609

Showing the most recent 10 out of 411 publications